STOCK TITAN

Inflarx Stock Price, News & Analysis

IFRX Nasdaq

Welcome to our dedicated page for Inflarx news (Ticker: IFRX), a resource for investors and traders seeking the latest updates and insights on Inflarx stock.

InflaRx NV (IFRX) is a clinical-stage biopharmaceutical company pioneering targeted therapies for inflammatory and autoimmune diseases through its proprietary C5a inhibition technology. This page provides investors and healthcare professionals with a comprehensive repository of official updates, including clinical trial progress, regulatory developments, and strategic partnerships.

Access real-time updates on ifx-1 and ifx-2, the company's lead monoclonal antibody candidates, alongside analysis of their potential impact on conditions like hidradenitis suppurativa and ANCA-associated vasculitis. Our curated news feed ensures you stay informed about milestones in drug development without promotional bias.

Key coverage areas include phase trial results, FDA/EMA regulatory communications, patent filings, and collaborative research initiatives. All content is vetted for accuracy and relevance to support data-driven decision-making.

Bookmark this page for streamlined access to InflaRx's latest advancements in complement system modulation. Check regularly for authoritative updates directly impacting the biopharmaceutical investment landscape.

Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX) has been awarded a grant of up to EUR 43.7 million by the German government to support the development of vilobelimab for COVID-19 treatment. The initial tranche of EUR 25.8 million will reimburse 80% of specified expenses related to clinical development and manufacturing. The grant aims to expedite vilobelimab's development and secure manufacturing capacity in Germany. The ongoing Phase III study is fully enrolled, with top-line results expected in Q1 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.46%
Tags
covid-19
-
Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX) has completed enrollment in the Phase III portion of its vilobelimab study, which targets severe COVID-19 patients. The study enrolled 369 patients in multiple countries, including Europe and South America. Topline results are anticipated in Q1 2022, focusing on 28-day all-cause mortality among other endpoints. The Phase II part showed a mortality rate of 13% in the vilobelimab arm versus 27% in the control group. Vilobelimab is a promising anti-C5a antibody aimed at treating various inflammatory conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.14%
Tags
covid-19
-
Rhea-AI Summary

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company, announces that CEO Prof. Niels C. Riedemann will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on demand from 7:00 AM EDT / 1:00 PM CET on September 13, 2021. A webcast of the event can be accessed for 90 days on the InflaRx website in the Investors section.

InflaRx focuses on developing anti-inflammatory therapeutics targeting the complement system, specifically through its proprietary anti-C5a technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
conferences
Rhea-AI Summary

InflaRx (Nasdaq: IFRX) has received FDA feedback from its Type A meeting, supporting a pivotal development program for vilobelimab in treating moderate to severe Hidradenitis Suppurativa (HS). The FDA acknowledged that targeting pain and draining lesions represents a clinically meaningful outcome, leading to a new primary efficacy endpoint. The company aims to submit the updated study protocol in Q4 2021, following FDA approval. With a significant need for new treatments, vilobelimab is positioned as a potential solution for HS patients suffering from debilitating symptoms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.41%
Tags
none
-
Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX) announced encouraging results from its Phase IIa study of vilobelimab in Pyoderma Gangraenosum (PG), with four out of ten evaluable patients showing a clinical response at day 99. Three patients achieved complete closure of their target lesions, with treatment being well tolerated and no significant adverse events during dose escalation. The study enrolled 19 patients, with doses of vilobelimab ranging from 800mg to 2400mg. The ongoing study aims to assess vilobelimab's efficacy and safety further, especially in the higher dose cohort.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
-
Rhea-AI Summary

InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company, will present at the BTIG Virtual Biotechnology Conference on August 10, 2021. The event will feature a fireside chat with CEO Prof. Niels C. Riedemann, discussing the company's pipeline and upcoming catalysts at 9:00 am EDT. InflaRx is focused on developing first-in-class inhibitors of C5a, a key inflammatory mediator involved in various autoimmune diseases. Founded in 2007, the company operates in Germany and the USA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
conferences
Rhea-AI Summary

InflaRx announced significant progress in its clinical trials and a financial update for Q2 2021. The severe COVID-19 trial has enrolled 299 patients, with an independent data monitoring committee recommending continuation. A Type A meeting has been requested with the FDA regarding the Phase III study for Hidradenitis Suppurativa. The first patients have been dosed in a Phase II trial for Cutaneous Squamous Cell Carcinoma. As of June 30, 2021, financial assets total approximately €127.5 million, though the company reported a net loss of €20.9 million for the first half of 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.2%
Tags
none
-
Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX) will virtually present at the Raymond James Human Health Innovation Conference from June 21-23, 2021. Prof. Niels C. Riedemann, CEO and Founder, will engage in a fireside chat on June 23 at 10:00 am EDT, discussing the company's pipeline and forthcoming catalysts. A live webcast will be available on InflaRx's website, with a replay accessible post-event. The company specializes in developing anti-inflammatory therapeutics targeting the complement system, specifically using its proprietary anti-C5a technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
conferences
-
Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX) has initiated a Phase II clinical trial evaluating vilobelimab, both as a standalone treatment and in combination with pembrolizumab, for patients with PD-1 or PD-L1 inhibitor-resistant locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). The trial aims to enroll around 70 patients and assess the safety and anti-tumor efficacy of vilobelimab. Given the poor prognosis of advanced cSCC, the development of vilobelimab, a monoclonal antibody targeting C5a, could provide vital treatment options for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.51%
Tags
Rhea-AI Summary

InflaRx N.V. (Nasdaq: IFRX) announced the appointment of Tony Gibney as a Non-Executive Director to its Board, approved by shareholders at the 2021 annual meeting. Gibney, a seasoned biotech executive and former investment banker, brings extensive experience in financing and M&A transactions. He aims to support InflaRx's strategy in complement C5a inhibition, a critical area for autoimmune diseases. Mark Kübler and Lina Ma were re-elected as board members, who have significantly contributed to the company since its IPO in 2017.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.68%
Tags
management

FAQ

What is the current stock price of Inflarx (IFRX)?

The current stock price of Inflarx (IFRX) is $0.892 as of July 14, 2025.

What is the market cap of Inflarx (IFRX)?

The market cap of Inflarx (IFRX) is approximately 55.6M.
Inflarx

Nasdaq:IFRX

IFRX Rankings

IFRX Stock Data

55.55M
63.42M
6.44%
19.51%
0.84%
Biotechnology
Healthcare
Link
Germany
Jena